Stock SNDX SYNDAX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
21.62 USD -0.46% Intraday chart for Syndax Pharmaceuticals, Inc. -5.22% +0.05%
Apr. 08 Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session CI
Mar. 28 Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
PR
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
AQ
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
CI
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
CI
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia
AQ
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
MT
Syndax Says Revumenib NDA Granted FDA Priority Review
DJ
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
CI
JPMorgan Raises Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating
MT
Sector Update: Health Care Stocks Rise Monday Afternoon
MT
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer
MT
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
PR
Syndax Pharmaceuticals, Inc. Announces Executive Changes
CI
Transcript : Syndax Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
Syndax: Q4 Earnings Snapshot
AQ
Transcript : Syndax Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNDX Stock
  4. News Syndax Pharmaceuticals, Inc.